Redmile Group Invests $49 Million in Scholar Rock as Apitegromab Nears Regulatory Resubmission
核心洞察
Redmile Group (搜索) acquired 1.3 million shares of Scholar Rock for $49.37 million, increasing its stake to 16.94% of fund assets.
Scholar Rock plans to resubmit its Biologics License Application for apitegromab in spinal muscular atrophy (搜索) with potential U.S. launch in 2026.
The company maintains strong financial position with $365 million in cash runway projected into 2027, reducing dilution risk.
Redmile Group (搜索), LLC significantly increased its position in Scholar Rock Holding Corporation (搜索) (NASDAQ: SRRK) with a $49.37 million investment, acquiring 1,316,390 shares during the fourth quarter according to a February 17, 2026 SEC filing. The biotech-focused fund now holds Scholar Rock as its largest position, representing 16.94% of its 13F reportable assets under management.
Strategic Investment Timing
The substantial investment comes as Scholar Rock enters 2026 with what the company describes as "a clear catalyst path." According to an announcement last month, Scholar Rock plans to resubmit its Biologics License Application for apitegromab in spinal muscular atrophy (搜索) and anticipates a potential U.S. launch following approval this year.
Scholar Rock's shares were priced at $46.45 as of February 17, 2026, representing a 25.7% increase over the past year and outperforming the S&P 500 by 13.39 percentage points. The quarter-end value of Redmile's position increased by $84.58 million, reflecting both the additional shares acquired and market price movements.
Company Pipeline and Platform
Scholar Rock Holding Corporation (搜索) operates as a clinical-stage biotechnology company specializing in the discovery and development of therapies that modulate protein growth factor (搜索) signaling. The company develops biopharmaceutical products targeting serious diseases, including apitegromab for spinal muscular atrophy (搜索) and SRK-181 for cancer (搜索) therapy resistance.
The firm operates a research-driven model focused on discovering and advancing protein growth factor (搜索) inhibitors, with revenue potential from product commercialization and strategic collaborations. It serves patients with neuromuscular disorders (搜索), cancer (搜索), and fibrotic diseases (搜索), targeting healthcare providers and biopharmaceutical partners.
Beyond apitegromab, Scholar Rock's pipeline includes programs in facioscapulohumeral muscular dystrophy (搜索) (FSHD) and the SRK-439 myostatin (搜索) inhibitor, expanding the company's therapeutic optionality across multiple indications.
Financial Position and Market Valuation
Scholar Rock maintains a strong balance sheet with approximately $365 million in cash as of December 31, with runway projected into 2027. This financial position reduces near-term dilution risk, which represents a key consideration for long-term biotech investors.
The company currently holds a market capitalization of $4.78 billion, though it reported a net income loss of $353.43 million over the trailing twelve months, typical for clinical-stage biotechnology companies focused on drug development rather than commercialization.
Fund Concentration Strategy
Redmile Group (搜索)'s investment strategy demonstrates significant concentration in clinical-stage biotechnology names. Following this transaction, Scholar Rock now represents roughly 17% of the fund's assets, alongside other high-conviction biotech positions including Krystal Biotech ($167.08 million), Nurix Therapeutics ($153.54 million), Stoke Therapeutics ($128.04 million), and Immunome ($122.83 million).
This concentration strategy amplifies both upside potential and binary risk associated with clinical-stage drug development, where regulatory outcomes can significantly impact valuations. The purchase signals Redmile's willingness to increase exposure to volatility rather than reduce positions around regulatory catalysts.